节点文献
重组人β2糖蛋白1第一结构域二聚体作为抗磷脂抗体综合征B细胞耐受原的初步探讨
Preliminary approach on application of recombinant human 2-glycoprotein-1 domain Ⅰ dimer as B lymphocyte tolerogen
【摘要】 目的:探讨重组人β2糖蛋白1第一结构域二聚体(rhβ2-GP1-DⅠ2)对重组人β2糖蛋白1(rhβ2-GP1)免疫小鼠β2-GP1特异性B细胞反应的抑制作用。方法:应用固相ELISA方法,检测静脉注射rhβ2-GP1-DⅠ2后免疫小鼠产生的抗β2糖蛋白1抗体(anti-β2-GP1)滴度及anti-β2-GP1产生水平比率;应用ELISPOT方法,检测静脉注射rhβ2-GP1-DⅠ2后免疫小鼠脾脏β2-GP1特异性抗体形成细胞(AFC)数量。结果:静脉注射rhβ2-GP1-DⅠ2后,与对照组比较,rhβ2-GP1免疫小鼠βanti-β2-GP1滴度明显降低(P<0.01),anti-β2-GP1产生水平比率下降,β2-GP1特异性AFC数量明显减少(P<0.01)。结论:静脉注射rhβ2-GP1-DⅠ2能够抑制rhβ2-GP1免疫小鼠β2-GP1特异性B细胞的反应能力。
【Abstract】 Objective To investigate the suppression to 2-glycoprotein-1-specific B cell response by human recombinant 2-glycoprotein-1 domain Ⅰ dimer(rhβ2-GP1-DⅠ2) in rhβ2-GP1 immunized mice.Methods The effects of treatment using rhβ2-GP1-DⅠ2 on titer and ratio of anti-β2-GP1 were analyzed by solid phase ELISA.The number of splenic β2-GP1-specific antibody-forming cells(AFC) was counted by ELISPOT.Results The levels of anti-β2-GP1 from rhβ2-GP1 immunized mice treated with rhβ2-GP1-DⅠ2 were significantly decreased compared with those in negative controls(P<0.01).The reductions paralleled by decreases in ratio of anti-β2-GP1(P<0.01);β2-GP1-specific AFC decreased at the same time(P<0.01).Conclusion Intravenous administration of rhβ2-GP1-DⅠ2 could inhibit the 2-glycoprotein-1-specific B cell response in rhβ2-GP1 immunized mice.
【Key words】 recombinant human 2-glycoprotein-1; domain Ⅰ dimer; anti-phospholipid antibody syndrome; B lymphocyte tolerogen;
- 【文献出处】 吉林大学学报(医学版) ,Journal of Jilin University(Medicine Edition) , 编辑部邮箱 ,2009年04期
- 【分类号】R392
- 【下载频次】174